Physician profile
Damon Suttle
NPI 1821786393
$3,080.48
in general payments reported to CMS, 2019-2025
24 companies · $1,317 in 2025
The $1,317 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,764 · 2025: $1,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,080.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $708.03 | 2024-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Astrazeneca Pharmaceuticals LP | $570.54 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $356.94 | 2024-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $229.07 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $157.14 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $113.77 | 2024-2025 | Cologuard Collection Kit |
| Nevro Corp. | $111.98 | 2024 | Senza |
| Pfizer INC. | $97.97 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $92.73 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.16 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $79.27 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $76.13 | 2024-2025 | |
| Lilly USA, LLC | $69.09 | 2024 | Mounjaro, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.93 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $56.08 | 2024 | Austedo Xr, Ajovy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.83 | 2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $39.50 | 2025 | Gemtesa |
| Corcept Therapeutics | $29.91 | 2024 | Korlym |
| Edwards Lifesciences Corporation | $22.88 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Nalu Medical, INC. | $18.69 | 2025 | Nalu Neurostimulation System |
| Eisai INC. | $18.16 | 2025 | |
| Astellas Pharma US INC | $15.77 | 2024 | Veozah |
| Amneal Pharmaceuticals LLC | $15.21 | 2025 | Unithroid |
| Globus Medical, INC. | $14.70 | 2025 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damon Suttle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.